Tag: molnupiravir

Research finds Paxlovid and Legevrio reduced COVID-19 hospitalization and death

New Cleveland Clinic-led research shows commonly used COVID-19 anti-viral drugs Paxlovid (nirmatrelvir) and Lagevrio (molnupiravir) reduce risk of hospitalization and…

By Staff , in COVID-19 , at December 10, 2023

Treating COVID-19 infection with molnupiravir does not decrease deaths or hospital admission in high-risk, vaccinated patients, but can lead to quicker recovery

Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated…

By Staff , in COVID-19 , at December 23, 2022

Variant type and patient sex affect molnupiravir efficacy, study finds

SARS-CoV-2 variants of concern and the biological sex of patients affect the efficacy of molnupiravir, the first orally available drug…

By Staff , in COVID-19 , at November 3, 2022

New analysis of investigational COVID antiviral drug molnupiravir shows it appears to clear virus equally well in immunocompromised patients and those who are immunocompetent

A new analysis of data on the ‘COVID-19 pill’ molnupiravir shows it appears to clear active SARS-CoV-2 virus equally well…

By Staff , in COVID-19 , at April 1, 2022

Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with COVID-19

Press release: Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that…

By Staff , in COVID-19 , at October 2, 2021